TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

Global Lung Cancer Diagnosis and Therapeutics Market Research Report 2023

Global Lung Cancer Diagnosis and Therapeutics Market Research Report 2023

  • Category:Life Sciences
  • Published on : 03 January 2023
  • Pages :97
  • Formats:
  • Report Code:SMR-7527509

Market Analysis and Insights: Global Lung Cancer Diagnosis Therapeutics Market

The global Lung Cancer Diagnosis Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Lung Cancer Diagnosis Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Lung Cancer Diagnosis Therapeutics market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Lung Cancer Diagnosis Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Lung Cancer Diagnosis Therapeutics market.

Global Lung Cancer Diagnosis Therapeutics Scope and Market Size

Lung Cancer Diagnosis and Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Lung Cancer Diagnosis and Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2030.
Segment by Type

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer

Segment by Application

  • Hospitals
  • Cancer Research Centers

By Region

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
  • Nordic Countries
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia
  • Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

By Company

  • AstraZeneca
  • Eli Lilly
  • Sanofi
  • ArQule
  • Daiichi Sankyo
  • Celgene
  • Merck
  • Pfizer
  • Boehringer Ingelheim
  • Roche
  • Genentech
  • GSK
  • Pharmacyclics
  • Novartis
  • Bayer
  • Bristol-Myers Squibb
  • Eisai
  • AbbVie

The information for each competitor/Company Profile includes:

  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Lung Cancer Diagnosis Therapeutics product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Lung Cancer Diagnosis Therapeutics, with price, sales, revenue, and global market share of Lung Cancer Diagnosis Therapeutics from 2019 to 2022.

Chapter 3, the Lung Cancer Diagnosis Therapeutics competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Lung Cancer Diagnosis Therapeutics breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Lung Cancer Diagnosis Therapeutics market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Lung Cancer Diagnosis Therapeutics.

Chapter 13, 14, and 15, to describe Lung Cancer Diagnosis Therapeutics sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

  • Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
  • Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
  • Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
  • Opportunities and Drivers: Identifying the Growing Demands and New Technology
  • Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

  • Estimates 2022-2027 2021-2025 Lung Cancer Diagnosis Therapeutics Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
  • Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
  • Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
  • 1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

TABLE OF CONTENTS

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Lung Cancer Diagnosis and Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2030
1.2.2 Non-Small Cell Lung Cancer
1.2.3 Small Cell Lung Cancer
1.3 Market by Application
1.3.1 Global Lung Cancer Diagnosis and Therapeutics Market Share by Application: 2018 VS 2022 VS 2030
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Lung Cancer Diagnosis and Therapeutics Market Perspective (2018-2030)
2.2 Lung Cancer Diagnosis and Therapeutics Growth Trends by Region
2.2.1 Lung Cancer Diagnosis and Therapeutics Market Size by Region: 2018 VS 2022 VS 2030
2.2.2 Lung Cancer Diagnosis and Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Region (2023-2030)
2.3 Lung Cancer Diagnosis and Therapeutics Market Dynamics
2.3.1 Lung Cancer Diagnosis and Therapeutics Industry Trends
2.3.2 Lung Cancer Diagnosis and Therapeutics Market Drivers
2.3.3 Lung Cancer Diagnosis and Therapeutics Market Challenges
2.3.4 Lung Cancer Diagnosis and Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Revenue
3.1.1 Global Top Lung Cancer Diagnosis and Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Lung Cancer Diagnosis and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Lung Cancer Diagnosis and Therapeutics Revenue
3.4 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio
3.4.1 Global Lung Cancer Diagnosis and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Diagnosis and Therapeutics Revenue in 2022
3.5 Lung Cancer Diagnosis and Therapeutics Key Players Head office and Area Served
3.6 Key Players Lung Cancer Diagnosis and Therapeutics Product Solution and Service
3.7 Date of Enter into Lung Cancer Diagnosis and Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Lung Cancer Diagnosis and Therapeutics Breakdown Data by Type
4.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Type (2023-2030)
5 Lung Cancer Diagnosis and Therapeutics Breakdown Data by Application
5.1 Global Lung Cancer Diagnosis and Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Application (2023-2030)
6 North America
6.1 North America Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
6.2 North America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
6.3 North America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
7.2 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
7.3 Europe Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
8.2 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
8.3 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
9.2 Latin America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
9.3 Latin America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size (2018-2030)
10.2 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023)
10.3 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Lung Cancer Diagnosis and Therapeutics Introduction
11.1.4 AstraZeneca Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.1.5 AstraZeneca Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Detail
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Lung Cancer Diagnosis and Therapeutics Introduction
11.2.4 Eli Lilly Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.2.5 Eli Lilly Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Lung Cancer Diagnosis and Therapeutics Introduction
11.3.4 Sanofi Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.3.5 Sanofi Recent Development
11.4 ArQule
11.4.1 ArQule Company Detail
11.4.2 ArQule Business Overview
11.4.3 ArQule Lung Cancer Diagnosis and Therapeutics Introduction
11.4.4 ArQule Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.4.5 ArQule Recent Development
11.5 Daiichi Sankyo
11.5.1 Daiichi Sankyo Company Detail
11.5.2 Daiichi Sankyo Business Overview
11.5.3 Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Introduction
11.5.4 Daiichi Sankyo Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.5.5 Daiichi Sankyo Recent Development
11.6 Celgene
11.6.1 Celgene Company Detail
11.6.2 Celgene Business Overview
11.6.3 Celgene Lung Cancer Diagnosis and Therapeutics Introduction
11.6.4 Celgene Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.6.5 Celgene Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Lung Cancer Diagnosis and Therapeutics Introduction
11.7.4 Merck Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.7.5 Merck Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Lung Cancer Diagnosis and Therapeutics Introduction
11.8.4 Pfizer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 Boehringer Ingelheim
11.9.1 Boehringer Ingelheim Company Detail
11.9.2 Boehringer Ingelheim Business Overview
11.9.3 Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Introduction
11.9.4 Boehringer Ingelheim Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.9.5 Boehringer Ingelheim Recent Development
11.10 Roche
11.10.1 Roche Company Detail
11.10.2 Roche Business Overview
11.10.3 Roche Lung Cancer Diagnosis and Therapeutics Introduction
11.10.4 Roche Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.10.5 Roche Recent Development
11.11 Genentech
11.11.1 Genentech Company Detail
11.11.2 Genentech Business Overview
11.11.3 Genentech Lung Cancer Diagnosis and Therapeutics Introduction
11.11.4 Genentech Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.11.5 Genentech Recent Development
11.12 GSK
11.12.1 GSK Company Detail
11.12.2 GSK Business Overview
11.12.3 GSK Lung Cancer Diagnosis and Therapeutics Introduction
11.12.4 GSK Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.12.5 GSK Recent Development
11.13 Pharmacyclics
11.13.1 Pharmacyclics Company Detail
11.13.2 Pharmacyclics Business Overview
11.13.3 Pharmacyclics Lung Cancer Diagnosis and Therapeutics Introduction
11.13.4 Pharmacyclics Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.13.5 Pharmacyclics Recent Development
11.14 Novartis
11.14.1 Novartis Company Detail
11.14.2 Novartis Business Overview
11.14.3 Novartis Lung Cancer Diagnosis and Therapeutics Introduction
11.14.4 Novartis Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.14.5 Novartis Recent Development
11.15 Bayer
11.15.1 Bayer Company Detail
11.15.2 Bayer Business Overview
11.15.3 Bayer Lung Cancer Diagnosis and Therapeutics Introduction
11.15.4 Bayer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.15.5 Bayer Recent Development
11.16 Bristol-Myers Squibb
11.16.1 Bristol-Myers Squibb Company Detail
11.16.2 Bristol-Myers Squibb Business Overview
11.16.3 Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Introduction
11.16.4 Bristol-Myers Squibb Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.16.5 Bristol-Myers Squibb Recent Development
11.17 Eisai
11.17.1 Eisai Company Detail
11.17.2 Eisai Business Overview
11.17.3 Eisai Lung Cancer Diagnosis and Therapeutics Introduction
11.17.4 Eisai Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.17.5 Eisai Recent Development
11.18 AbbVie
11.18.1 AbbVie Company Detail
11.18.2 AbbVie Business Overview
11.18.3 AbbVie Lung Cancer Diagnosis and Therapeutics Introduction
11.18.4 AbbVie Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
11.18.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Lung Cancer Diagnosis and Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2030
Table 2. Key Players of Non-Small Cell Lung Cancer
Table 3. Key Players of Small Cell Lung Cancer
Table 4. Global Lung Cancer Diagnosis and Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2030
Table 5. Global Lung Cancer Diagnosis and Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2030
Table 6. Global Lung Cancer Diagnosis and Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 7. Global Lung Cancer Diagnosis and Therapeutics Market Share by Region (2018-2023)
Table 8. Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Region (2023-2030) & (US$ Million)
Table 9. Global Lung Cancer Diagnosis and Therapeutics Market Share by Region (2023-2030)
Table 10. Lung Cancer Diagnosis and Therapeutics Market Trends
Table 11. Lung Cancer Diagnosis and Therapeutics Market Drivers
Table 12. Lung Cancer Diagnosis and Therapeutics Market Challenges
Table 13. Lung Cancer Diagnosis and Therapeutics Market Restraints
Table 14. Global Lung Cancer Diagnosis and Therapeutics Revenue by Players (2018-2023) & (US$ Million)
Table 15. Global Lung Cancer Diagnosis and Therapeutics Market Share by Players (2018-2023)
Table 16. Global Top Lung Cancer Diagnosis and Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Diagnosis and Therapeutics as of 2022)
Table 17. Ranking of Global Top Lung Cancer Diagnosis and Therapeutics Companies by Revenue (US$ Million) in 2022
Table 18. Global 5 Largest Players Market Share by Lung Cancer Diagnosis and Therapeutics Revenue (CR5 and HHI) & (2018-2023)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Lung Cancer Diagnosis and Therapeutics Product Solution and Service
Table 21. Date of Enter into Lung Cancer Diagnosis and Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Lung Cancer Diagnosis and Therapeutics Market Size by Type (2018-2023) & (US$ Million)
Table 24. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Type (2018-2023)
Table 25. Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Type (2023-2030) & (US$ Million)
Table 26. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Type (2023-2030)
Table 27. Global Lung Cancer Diagnosis and Therapeutics Market Size by Application (2018-2023) & (US$ Million)
Table 28. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Application (2018-2023)
Table 29. Global Lung Cancer Diagnosis and Therapeutics Forecasted Market Size by Application (2023-2030) & (US$ Million)
Table 30. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Application (2023-2030)
Table 31. North America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 32. North America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030) & (US$ Million)
Table 33. Europe Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 34. Europe Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030) & (US$ Million)
Table 35. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size by Region (2018-2023) & (US$ Million)
Table 36. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size by Region (2023-2030) & (US$ Million)
Table 37. Latin America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 38. Latin America Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030) & (US$ Million)
Table 39. Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size by Country (2018-2023) & (US$ Million)
Table 40. Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size by Country (2023-2030) & (US$ Million)
Table 41. AstraZeneca Company Detail
Table 42. AstraZeneca Business Overview
Table 43. AstraZeneca Lung Cancer Diagnosis and Therapeutics Product
Table 44. AstraZeneca Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 45. AstraZeneca Recent Development
Table 46. Eli Lilly Company Detail
Table 47. Eli Lilly Business Overview
Table 48. Eli Lilly Lung Cancer Diagnosis and Therapeutics Product
Table 49. Eli Lilly Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 50. Eli Lilly Recent Development
Table 51. Sanofi Company Detail
Table 52. Sanofi Business Overview
Table 53. Sanofi Lung Cancer Diagnosis and Therapeutics Product
Table 54. Sanofi Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 55. Sanofi Recent Development
Table 56. ArQule Company Detail
Table 57. ArQule Business Overview
Table 58. ArQule Lung Cancer Diagnosis and Therapeutics Product
Table 59. ArQule Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 60. ArQule Recent Development
Table 61. Daiichi Sankyo Company Detail
Table 62. Daiichi Sankyo Business Overview
Table 63. Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Product
Table 64. Daiichi Sankyo Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 65. Daiichi Sankyo Recent Development
Table 66. Celgene Company Detail
Table 67. Celgene Business Overview
Table 68. Celgene Lung Cancer Diagnosis and Therapeutics Product
Table 69. Celgene Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 70. Celgene Recent Development
Table 71. Merck Company Detail
Table 72. Merck Business Overview
Table 73. Merck Lung Cancer Diagnosis and Therapeutics Product
Table 74. Merck Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 75. Merck Recent Development
Table 76. Pfizer Company Detail
Table 77. Pfizer Business Overview
Table 78. Pfizer Lung Cancer Diagnosis and Therapeutics Product
Table 79. Pfizer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Boehringer Ingelheim Company Detail
Table 82. Boehringer Ingelheim Business Overview
Table 83. Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Product
Table 84. Boehringer Ingelheim Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 85. Boehringer Ingelheim Recent Development
Table 86. Roche Company Detail
Table 87. Roche Business Overview
Table 88. Roche Lung Cancer Diagnosis and Therapeutics Product
Table 89. Roche Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 90. Roche Recent Development
Table 91. Genentech Company Detail
Table 92. Genentech Business Overview
Table 93. Genentech Lung Cancer Diagnosis and TherapeuticsProduct
Table 94. Genentech Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 95. Genentech Recent Development
Table 96. GSK Company Detail
Table 97. GSK Business Overview
Table 98. GSK Lung Cancer Diagnosis and TherapeuticsProduct
Table 99. GSK Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 100. GSK Recent Development
Table 101. Pharmacyclics Company Detail
Table 102. Pharmacyclics Business Overview
Table 103. Pharmacyclics Lung Cancer Diagnosis and TherapeuticsProduct
Table 104. Pharmacyclics Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 105. Pharmacyclics Recent Development
Table 106. Novartis Company Detail
Table 107. Novartis Business Overview
Table 108. Novartis Lung Cancer Diagnosis and TherapeuticsProduct
Table 109. Novartis Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 110. Novartis Recent Development
Table 111. Bayer Company Detail
Table 112. Bayer Business Overview
Table 113. Bayer Lung Cancer Diagnosis and TherapeuticsProduct
Table 114. Bayer Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 115. Bayer Recent Development
Table 116. Bristol-Myers Squibb Company Detail
Table 117. Bristol-Myers Squibb Business Overview
Table 118. Bristol-Myers Squibb Lung Cancer Diagnosis and TherapeuticsProduct
Table 119. Bristol-Myers Squibb Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 120. Bristol-Myers Squibb Recent Development
Table 121. Eisai Company Detail
Table 122. Eisai Business Overview
Table 123. Eisai Lung Cancer Diagnosis and TherapeuticsProduct
Table 124. Eisai Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 125. Eisai Recent Development
Table 126. AbbVie Company Detail
Table 127. AbbVie Business Overview
Table 128. AbbVie Lung Cancer Diagnosis and TherapeuticsProduct
Table 129. AbbVie Revenue in Lung Cancer Diagnosis and Therapeutics Business (2018-2023) & (US$ Million)
Table 130. AbbVie Recent Development
Table 131. Research Programs/Design for This Report
Table 132. Key Data Information from Secondary Sources
Table 133. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Lung Cancer Diagnosis and Therapeutics Market Share by Type: 2022 VS 2030
Figure 2. Non-Small Cell Lung Cancer Features
Figure 3. Small Cell Lung Cancer Features
Figure 4. Global Lung Cancer Diagnosis and Therapeutics Market Share by Application in 2022 & 2030
Figure 5. Hospitals Case Studies
Figure 6. Cancer Research Centers Case Studies
Figure 7. Lung Cancer Diagnosis and Therapeutics Report Years Considered
Figure 8. Global Lung Cancer Diagnosis and Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2030
Figure 9. Global Lung Cancer Diagnosis and Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2030
Figure 10. Global Lung Cancer Diagnosis and Therapeutics Market Share by Region: 2022 VS 2030
Figure 11. Global Lung Cancer Diagnosis and Therapeutics Market Share by Players in 2022
Figure 12. Global Top Lung Cancer Diagnosis and Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Diagnosis and Therapeutics as of 2022)
Figure 13. The Top 10 and 5 Players Market Share by Lung Cancer Diagnosis and Therapeutics Revenue in 2022
Figure 14. North America Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 15. North America Lung Cancer Diagnosis and Therapeutics Market Share by Country (2018-2030)
Figure 16. United States Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 17. Canada Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 18. Europe Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 19. Europe Lung Cancer Diagnosis and Therapeutics Market Share by Country (2018-2030)
Figure 20. Germany Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 21. France Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 22. U.K. Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 23. Italy Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 24. Russia Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 25. Nordic Countries Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 26. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 27. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Market Share by Region (2018-2030)
Figure 28. China Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 29. Japan Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 30. South Korea Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 31. Southeast Asia Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 32. India Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 33. Australia Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 34. Latin America Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 35. Latin America Lung Cancer Diagnosis and Therapeutics Market Share by Country (2018-2030)
Figure 36. Mexico Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 37. Brazil Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 38. Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 39. Middle East & Africa Lung Cancer Diagnosis and Therapeutics Market Share by Country (2018-2030)
Figure 40. Turkey Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 41. Saudi Arabia Lung Cancer Diagnosis and Therapeutics Market Size YoY Growth (2018-2030) & (US$ Million)
Figure 42. AstraZeneca Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 43. Eli Lilly Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 44. Sanofi Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 45. ArQule Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 46. Daiichi Sankyo Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 47. Celgene Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 48. Merck Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 49. Pfizer Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 50. Boehringer Ingelheim Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 51. Roche Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 52. Genentech Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 53. GSK Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 54. Pharmacyclics Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 55. Novartis Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 56. Bayer Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 58. Eisai Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 59. AbbVie Revenue Growth Rate in Lung Cancer Diagnosis and Therapeutics Business (2018-2023)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Offer REPORT BUYING OPTIONS

USD GBP EURO YEN Single User Price
USD GBP EURO YEN Multi User Price
USD GBP EURO YEN Enterprise Price

---- OR ----

Frequently Asked Questions ?

  • Upto 24 hrs - Working days
  • Upto 48 hrs max - Weekends and public holidays
  • Single User License
    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License
    A license granted to multiple users.

  • Site License
    A license granted to a single business site/establishment.

  • Corporate License, Global License
    A license granted to all employees within organisation access to the product.
  • Online Payments with PayPal and CCavenue
  • Wire Transfer/Bank Transfer
  • Email
  • Hard Copy

Our Key Features

  • Data Accuracy and Reliability
  • Data Security
  • Customized Research
  • Trustworthy
  • Competitive Offerings
check discount